| ◆英語タイトル：Global Congestive Heart Failure Drugs Market Size study & Forecast, by Type (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2022-2029
|
 | ◆商品コード：BZW23FE0115
◆発行会社（リサーチ会社）：Bizwit Research & Consulting
◆発行日：2023年1月29日
◆ページ数：約200
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆産業分野：医薬品
|
◆販売価格オプション
（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Bizwit Research社は、2021年に約61.5億ドルであった世界のうっ血性心不全薬市場規模は、2022年から2029年の間にCAGR 14.6％増加すると予想しています。本書は、うっ血性心不全薬の世界市場について調査・分析を行い、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、種類別（ACE阻害剤、アンジオテンシン2受容体遮断薬、ベータ遮断薬、利尿薬、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他地域）分析、競争分析、調査プロセスなどの内容をまとめています。また、本書で記載されている企業情報には、Bayer AG、Novartis AG、Merck & Co., Inc.、AstraZeneca、Bristol-Myers Squibb Company、Amgen Inc.、Boehringer Ingelheim International GmbH、Pfizer, Inc.、Johnson & Johnson Services, Inc.、Otsuka Pharmaceutical Co., Ltd.などが含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界うっ血性心不全薬市場規模：種類別
- ACE阻害剤の市場規模
- アンジオテンシン2受容体遮断薬の市場規模
- ベータ遮断薬の市場規模
- 利尿薬の市場規模
- その他うっ血性心不全薬の市場規模
・世界うっ血性心不全薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のうっ血性心不全薬市場規模：地域別
- 北米のうっ血性心不全薬市場
- ヨーロッパのうっ血性心不全薬市場
- アジア太平洋のうっ血性心不全薬市場
- 中南米のうっ血性心不全薬市場
- その他地域のうっ血性心不全薬市場
・競争分析
・調査プロセス |
Global Congestive Heart Failure Drugs Market is valued at approximately USD 6.15 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 14.60% over the forecast period 2022-2029. Congestive heart failure (CHF) is a chronic health condition that reduces the pumping of blood in the heart and impacts the ability of the heart muscle. The CHF drugs are specially designed drugs that are used to cure this health problem and aid in increasing the ability of the heart to pump blood effectively. Factors such as the increasing geriatric population, rising product approvals, coupled with growing healthcare expenditure are reinforcing the market demand around the world.
The rising incidences of Congestive Heart Failure (CHF) is a major concern that leads to high morbidity and mortality rate. The Global Health Data Exchange registry reported that the prevalence of congestive heart failure disease was estimated to account for approximately around 64.34 million cases globally, and in the U.S., the incidences were recorded with 5.5 million in 2022. Therefore, the growing cases of CHF are acting as a catalyzing factor for market growth. In addition, the growing R&D for drug development, as well as the strong clinical drugs pipeline are offering various lucrative opportunities over the forecasting years. However, the availability of generic and off-label drugs in the market and poor reimbursement scenarios in developing countries are challenging the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Congestive Heart Failure Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the rise in patient awareness, along with the rising government initiatives and implementation of several policies. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increasing prevalence of congestive heart failure, as well as rising healthcare expenditure in the regional market space.
Major market players included in this report are:
Bayer AG
Novartis AG
Merck & Co., Inc.
AstraZeneca
Bristol-Myers Squibb Company
Amgen Inc.
Boehringer Ingelheim International GmbH
Pfizer, Inc.
Johnson & Johnson Services, Inc.
Otsuka Pharmaceutical Co., Ltd.
Recent Developments in the Market:
In February 2021, AstraZeneca declared the successful regulatory approval of Forxiga in China. The product has already received approval in the U.S., Europe, and Japan, which indicates heart failure with or without type-2 diabetes in adults.
Global Congestive Heart Failure Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
ACE Inhibitors
Angiotensin 2 Receptor Blockers
Beta Blockers
Diuretics
Aldosterone Antagonists
Inotropes
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Congestive Heart Failure Drugs Market, by Region, 2019-2029 (USD Billion)
1.2.2. Congestive Heart Failure Drugs Market, by Type, 2019-2029 (USD Billion)
1.2.3. Congestive Heart Failure Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Congestive Heart Failure Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Congestive Heart Failure Drugs Market Dynamics
3.1. Congestive Heart Failure Drugs Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising incidences of Congestive heart failure (CHF)
3.1.1.2. Increasing product approvals
3.1.2. Market Challenges
3.1.2.1. Availability of generic and off-label drugs in the market
3.1.2.2. Poor reimbursement scenarios in developing countries
3.1.3. Market Opportunities
3.1.3.1. Growing R&D for drug development
3.1.3.2. Strong clinical drugs pipeline
Chapter 4. Global Congestive Heart Failure Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Congestive Heart Failure Drugs Market, by Type
6.1. Market Snapshot
6.2. Global Congestive Heart Failure Drugs Market by Type, Performance – Potential Analysis
6.3. Global Congestive Heart Failure Drugs Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Congestive Heart Failure Drugs Market, Sub Segment Analysis
6.4.1. ACE Inhibitors
6.4.2. Angiotensin 2 Receptor Blockers
6.4.3. Beta Blockers
6.4.4. Diuretics
6.4.5. Aldosterone Antagonists
6.4.6. Inotropes
6.4.7. Others
Chapter 7. Global Congestive Heart Failure Drugs Market, by Distribution Channel
7.1. Market Snapshot
7.2. Global Congestive Heart Failure Drugs Market by Distribution Channel, Performance – Potential Analysis
7.3. Global Congestive Heart Failure Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
7.4. Congestive Heart Failure Drugs Market, Sub Segment Analysis
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
Chapter 8. Global Congestive Heart Failure Drugs Market, Regional Analysis
8.1. Congestive Heart Failure Drugs Market, Regional Market Snapshot
8.2. North America Congestive Heart Failure Drugs Market
8.2.1. U.S. Congestive Heart Failure Drugs Market
8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Congestive Heart Failure Drugs Market
8.3. Europe Congestive Heart Failure Drugs Market Snapshot
8.3.1. U.K. Congestive Heart Failure Drugs Market
8.3.2. Germany Congestive Heart Failure Drugs Market
8.3.3. France Congestive Heart Failure Drugs Market
8.3.4. Spain Congestive Heart Failure Drugs Market
8.3.5. Italy Congestive Heart Failure Drugs Market
8.3.6. Rest of Europe Congestive Heart Failure Drugs Market
8.4. Asia-Pacific Congestive Heart Failure Drugs Market Snapshot
8.4.1. China Congestive Heart Failure Drugs Market
8.4.2. India Congestive Heart Failure Drugs Market
8.4.3. Japan Congestive Heart Failure Drugs Market
8.4.4. Australia Congestive Heart Failure Drugs Market
8.4.5. South Korea Congestive Heart Failure Drugs Market
8.4.6. Rest of Asia Pacific Congestive Heart Failure Drugs Market
8.5. Latin America Congestive Heart Failure Drugs Market Snapshot
8.5.1. Brazil Congestive Heart Failure Drugs Market
8.5.2. Mexico Congestive Heart Failure Drugs Market
8.5.3. Rest of Latin America Congestive Heart Failure Drugs Market
8.6. Rest of The World Congestive Heart Failure Drugs Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Bayer AG
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Novartis AG
9.2.3. Merck & Co., Inc.
9.2.4. AstraZeneca
9.2.5. Bristol-Myers Squibb Company
9.2.6. Amgen Inc.
9.2.7. Boehringer Ingelheim International GmbH
9.2.8. Pfizer, Inc.
9.2.9. Johnson & Johnson Services, Inc.
9.2.10. Otsuka Pharmaceutical Co., Ltd.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
❖ 免責事項 ❖http://www.globalresearch.jp/disclaimer